The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers

Safa Najafi; Masoud Sadeghi; Mohammad Reza Shajari; Fatemeh Abasvandi; Kamran Mohebi

doi:10.5114/wo.2018.77048

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2018
vol. 22

Send email

Copy url:

abstract:

Original paper

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers

Safa Najafi

,

Masoud Sadeghi

,

Mohammad Reza Shajari

,

Fatemeh Abasvandi

,

Kamran Mohebi

Contemp Oncol (Pozn) 2018; 22 (2): 108-112

DOI: https://doi.org/10.5114/wo.2018.77048

Online publish date: 2018/06/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Najafi S, Sadeghi M, Shajari M, Abasvandi F, Mohebi K. The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. Contemporary Oncology/Współczesna Onkologia. 2018;22(2):108-112. doi:10.5114/wo.2018.77048.

APA

Najafi, S., Sadeghi, M., Shajari, M., Abasvandi, F.,  & Mohebi, K. (2018). The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. Contemporary Oncology/Współczesna Onkologia, 22(2), 108-112. https://doi.org/10.5114/wo.2018.77048

Chicago

Najafi, Safa, Masoud Sadeghi, Mohammad Reza Shajari, Fatemeh Abasvandi,  and Kamran Mohebi. 2018. "The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers". Contemporary Oncology/Współczesna Onkologia 22 (2): 108-112. doi:10.5114/wo.2018.77048.

Harvard

Najafi, S., Sadeghi, M., Shajari, M., Abasvandi, F.,  and Mohebi, K. (2018). The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. Contemporary Oncology/Współczesna Onkologia, 22(2), pp.108-112. https://doi.org/10.5114/wo.2018.77048

MLA

Najafi, Safa et al. "The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers." Contemporary Oncology/Współczesna Onkologia, vol. 22, no. 2, 2018, pp. 108-112. doi:10.5114/wo.2018.77048.

Vancouver

Najafi S, Sadeghi M, Shajari M, Abasvandi F, Mohebi K. The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. Contemporary Oncology/Współczesna Onkologia. 2018;22(2):108-112. doi:10.5114/wo.2018.77048.

PlumX metrics:

Aim of the study
This study aimed to assess the efficacy of anthracycline-based (AB) and non-anthracycline-based (nAB) adjuvant therapies in the human epidermal growth factor receptor 2 (HER2)-positive non-metastatic BC (nMBC) patients.

Material and methods
This retrospective study included women with HER2-positive BCs (stage I–III) treated with trastuzumab from 2008 to 2017. The patients were divided into two groups, including 196 patients in group AB and 67 in group nAB.

Results
Cox’s proportional hazard regression analysis showed no unfavourable predictors for five-year overall survival (OS) and disease-free survival (DFS) except for stage and hormone therapy. The OS rate was 67.9% in group AB and 80.6% in group nAB (p = 0.630). The DFS rate was 61.6% in group AB compared with 67.1% in group nAB (p = 0.447).

Conclusions
The results showed no difference between the efficacies of AB and nAB regimens in HER2-positive nMBCs in adjuvant setting. Therefore, selecting the nAB regimen can reduce the serious damage caused by the AB regimen.

keywords:

The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers

Safa Najafi , Masoud Sadeghi , Mohammad Reza Shajari , Fatemeh Abasvandi , Kamran Mohebi

breast cancer, HER2, trastuzumab, anthracycline, adjuvant therapy

Safa Najafi

,

Masoud Sadeghi

,

Mohammad Reza Shajari

,

Fatemeh Abasvandi

,

Kamran Mohebi